#China #Shanghai #Biopharmaceutical #Harbour BioMed #Yajie Li

Harbour BioMed's New Chapter with Yajie Li

On August 24, 2025, Harbour BioMed, a global player in the biopharmaceutical sector, unveiled its newest addition to the executive team, Yajie Li, who assumes the role of Chief Medical Officer (CMO). Operating from Shanghai, she will directly report to Dr. Jingsong Wang, the founder and CEO of Harbour BioMed. This strategic appointment comes at a time when the company is poised for significant growth in its innovative antibody therapeutics initiatives, especially in immunology and oncology.

In her new position, Yajie Li is set to steer clinical development, regulatory strategies, and medical affairs for the company’s clinical-stage projects. She will also play a critical role in assessing early-stage assets through the lens of unmet medical needs, clinical value, and scientific differentiation.

Yajie Li brings with her an impressive portfolio, boasting over ten years of experience in the pharmaceutical industry. Her career has spanned leadership positions in clinical development and regulatory affairs at notable companies like Merck, Johnson & Johnson, and Parexel, as well as at several biopharmaceutical firms in China including GenSci and Innovent. Importantly, prior to venturing into the corporate world, Li dedicated nine years as a Senior Medical Officer at the National Medical Products Administration of China (NMPA) and the Center for Drug Evaluation (CDE), contributing to a wide range of regulatory assessments across various therapeutic areas.

Dr. Jingsong Wang expressed his enthusiasm for Li's appointment, stating, "We are very pleased to welcome Yajie Li to our executive team. Her deep expertise in clinical development and regulatory science will further strengthen our capabilities as we advance our pipeline and grow into a therapeutically focused biopharma company. We look forward to her leadership in delivering transformative medicines to patients around the world.”

For her part, Yajie expressed her excitement about joining Harbour BioMed, remarking, "It is a great honor to join Harbour BioMed as Chief Medical Officer at this pivotal stage of its growth. The company’s cutting-edge antibody technology platform and global R&D strategy is well positioned to deliver innovative therapies in areas of high unmet need. I look forward to working with the team to accelerate clinical development, enhance regulatory alignment, and bring meaningful treatments to patients worldwide."

Li's academic credentials are as impressive as her professional ones. She holds a master’s degree in Rheumatology and Immunology from Peking Union Medical College, perfectly aligning her expertise with Harbour BioMed's commitment to innovation in healthcare.

Harbour BioMed (HKEX: 02142) is devoted to discovering and developing novel antibody therapeutics that meet significant medical needs in the realms of immunology and oncology. The company is focused on building a robust and differentiated pipeline through its internal R&D capabilities, global collaborations in co-discovery and co-development, and selective acquisitions.

The proprietary Harbour Mice® technology platform enables the generation of fully human monoclonal antibodies in distinct formats, catering to advanced therapeutic applications. This platform plays a vital role in Harbour BioMed’s strategy, especially with the innovative HCAb-based technologies that facilitate superior tumor-killing effects over traditional therapies.

With Yajie Li at the helm of the medical division, Harbour BioMed is set to elevate its strategic initiatives, further solidifying its position as a leading biopharmaceutical company committed to delivering next-generation therapeutic antibodies. For more information, visit Harbour BioMed's website.